Lepodisiran: A Promising Drug for Long-Term Reduction of Lipoprotein Lp(a)
TL;DR Summary
Bloomberg's website is displaying a message asking users to ensure their browser supports JavaScript and cookies, and that they are not blocking them from loading. Users are directed to contact the support team for assistance.
- Eli Lilly's Heart Drug Lepodisiran Cuts Lipoprotein Lp(a) for Year in Study Bloomberg
- Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug Medscape
- Trial Shows a Single Dose of an Experimental Therapy Reduces Lipoprotein(a), an Important Heart Disease Risk Factor, More than 94% for Nearly a Year Cleveland Clinic Newsroom
- Lepodisiran: Extended-Duration RNA Targets Lipoprotein Mirage News
- Lepodisiran, a Small Intefering RNA, Could Lower Lp(a) by More than 95% MD Magazine
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
0 min
vs 1 min read
Condensed
39%
57 → 35 words
Want the full story? Read the original article
Read on Bloomberg